Stockwinners Market Radar for March 03, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:06 EST Volaris reports February demand up 80.8%, capacity up 62.0% - In February, Volaris' capacity, measured in ASMs, increased 62.0% YoY, while demand, measured in RPMs, was up 80.8% YoY; load factor increased 8.6 pp YoY to 82.7%. In the month, Volaris transported 2.1 million passengers, an 86.7% increase YoY.

18:59 EST Digital Realty raises quarterly dividend by 5% to $1.22 - The common stock cash dividend will be paid on March 31, 2022 to common stockholders of record as of the close of business on March 15, 2022.

18:33 EST Ranger Oil names Julia Gwaltney as COO, effective immediately - Ranger Oil announced the promotion of Julia Gwaltney to the role of Senior Vice President and COO, effective immediately. Gwaltney joined the company in January 2021 as Senior Vice President of Development.

18:09 EST BRP Group to acquire Westwood Insurance Agency - BRP Group that the Company has entered into an agreement to acquire all of the outstanding equity interests of Westwood Insurance Agency. Based in West Hills, CA, and owned by QBE Holdings, Westwood is a full-service personal lines agency specializing in builder-sourced homeowners insurance. With annual revenues of approximately $81.8M, Westwood represents BRP Group's largest Partnership to date. The Partnership, BRP Group's nomenclature for a strategic acquisition, is expected to close on or around May 1, 2022, subject to certain closing conditions. Separate from the purchase of Westwood, Millennial Specialty Insurance, BRP Group's "MGA of the Future" platform, has entered into a Program Administrator Agreement with a QBE affiliate to assume operations of QBE's builder-sourced homeowners book, which is expected to add $200M of premium to MSI's homeowners MGA platform. Per the agreement, MSI will assume all MGA functions associated with the book of business, for which QBE will provide balance sheet capacity for a period of 5 years. MSI will not assume any balance sheet risk associated with the book of business. Morgan Stanley & Co. LLC acted as exclusive financial advisor to QBE in the transaction.

18:05 EST LGI Homes reports 499 home closings in February - LGI Homes announced it closed 499 homes in February 2022. As of February 28, 2022, the company had 89 active selling communities.

17:20 EST Pioneer Natural CEO sells over 22,000 common shares - In a regulatory filing, Pioneer Natural CEO Scott Sheffield disclosed the sale of 22,247 common shares of the company on March 3 at a price of $240.121 per share.

17:11 EST IDT's net2phone acquires Integra CCS, terms not disclosed - net2phone, a communications-as-a-service provider and subsidiary of IDT Corporation, announced that it has acquired Integra CCS, a contact-center-as-a-service provider operating in the Americas and Europe. "As the CCaaS and UCaaS markets continue their exceptional growth trajectories, businesses are gravitating to providers who can support integrated communications-as-a-service offerings," said Jonah Fink, CEO of net2phone. "With the Integra CCaaS platform, our powerful UCaaS solutions, and our industry-leading SIP trunking service, we can provide holistic solutions that deliver unbeatable value. Our channel partners in the US, Canada, Brazil and Mexico have begun to introduce these packages and are extremely enthusiastic about their potential." The acquisition of Integra was financed internally by IDT.

17:00 EST Cognex authorizes up to $500M stock buyback program - Cognex Corporation announced that the company's board of directors has authorized the purchase of up to $500M of Cognex common stock in open market transactions or otherwise, subject to market conditions and other relevant factors. Cognex recently completed its previous repurchase program, which was a $200M program authorized in March 2020. The board also reauthorized Cognex to establish Rule 10b5-1 trading plans that allow the company to repurchase shares at times when it might otherwise be prevented from doing so by securities laws or because of self-imposed trading blackout periods.

16:56 EST Smith & Wesson Brands drops 13% to $15.55 after Q3 results miss estimates

16:54 EST Yandex provides update on impact of Russia-Ukraine conflict - Yandex provided an update on the impact of current geopolitical developments on the company. The company said, "In recent days, a number of governments, including those of the United States, United Kingdom and European Union, have adopted new sanctions on specified persons and entities in Russia, including the Central Bank of Russia, and new export controls affecting specific, sensitive technologies. None of Yandex N.V., any of our subsidiaries, any of the members of our Board of Directors or management or any of our principal shareholders is a target of these sanctions. We are currently analyzing the new export controls and working closely with our vendors. None of the Yandex group companies operates in the defense, aerospace or maritime sectors that have been specifically targeted. We understand, however, that a number of companies based in the U.S., U.K., E.U. and elsewhere have indicated that that they are currently suspending supplies and services to customers in Russia. We believe that our current data center capacity and other technology critical to operations will allow us to continue to operate in the ordinary course for at least the next 12 to 18 months. In the event of any prolonged suspension of supplies of hardware, software or other technology used in our business or offerings, if we are unable to secure alternative sources, our operations could be materially adversely affected over time. In addition, we understand that many suppliers have announced intentions to suspend the sale of consumer goods to Russia, and several major shipping companies have ceased shipments to Russia; such actions, if prolonged, would result in a reduction of the number and selection of goods we are able to offer through Yandex.Market. As of February 28, 2022, Yandex had USD- and euro-denominated cash balances of approximately $615 million (of which a USD-equivalent of approximately $370 million is located outside of Russia) and approximately RUB 47 billion of ruble cash and cash equivalents as of February 28, 2022. We do not currently expect the blocking of certain financial institutions in Russia from the SWIFT system to affect our day-to-day operations. Any prolonged economic downturn in Russia as a result of sanctions, depreciation of the ruble or negative consumer sentiment could have a material adverse effect on our results. We are aware of press speculation regarding the possibility that the Russian government would take steps to effect changes of control of companies or assets in Russia in response to the sanctions that have been imposed. Although we are not aware of any plans in this regard, the majority of our operations and assets are located in Russia and therefore any such action would have a material adverse impact on the value of the Yandex group as a whole. Our parent company is registered in the Netherlands and has a number of direct and indirect subsidiaries located in countries outside of Russia. Our parent company and its direct and indirect foreign subsidiaries currently hold a USD-equivalent of approximately $370 million in cash as well as other assets and operations outside of Russia."

16:48 EST Sprouts Farmers Market announces new $600M share repurchase program - Sprouts Farmers Market announced that its Board of Directors authorized a new share repurchase program of $600M of its common shares on March 2 which replaces our current authorization with less than $100M remaining. The shares may be purchased on a discretionary basis from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans. This share repurchase program may be commenced, suspended or discontinued at any time and expires on December 31, 2024.

16:42 EST Riot Blockchain produced 436 BTC in February, up 189% YoY - Riot Blockchain announces production and operations update for February , status of miner shipments and deployment, and updates on the 400 megawatt infrastructure expansion at the Company's Whinstone facility in Rockdale, Texas . "Throughout the month of February Riot has continued to make progress on the first phase of its 200 MW immersion-cooled Bitcoin mining deployment, with over 10,000 S19j Pro Antminers now deployed in immersion-cooling tanks," said Jason Les, CEO of Riot Blockchain. "We have begun the performance evaluation process, and will be monitoring our immersion performance data closely over the next 60 days. As our team continues to build out our immersion operation, we are evaluating and assessing future opportunities to further leverage our expertise in immersion-cooling development and deployment." In February , Riot produced 436 BTC, an increase of approximately 189%, as compared to February 2021 production of 179 BTC. As of February 28 Riot held approximately 5,783 BTC, all produced by the Company's self-mining operations. Riot currently has a deployed fleet of approximately 38,310 miners, with a hash rate capacity of 3.9 exahash per second...By January 2023, Riot anticipates a total self-mining hash rate capacity of 12.8 EH/s, assuming full deployment of approximately 120,000 Antminer ASICs, but excluding any potential expected incremental productivity gains from the Company's utilization of 200 MW of immersion-cooling infrastructure. Approximately 97% of Riot's self-mining fleet will consist of the latest generation S19 series miner model. Upon full deployment of all currently contracted miners, the Company's total self-mining fleet will consume approximately 370 MW of energy. In addition to the Company's self-mining operations, Riot's Whinstone Facility hosts approximately 200 MW of institutional Bitcoin mining clients.

16:36 EST SPX Flow stockholders approve merger with Lone Star Funds affiliate - SPX Flow's stockholders approved the proposed merger of the company and Redwood Star Merger Sub, a Delaware corporation and a wholly owned subsidiary of LSF11 Redwood Acquisitions, a Delaware limited liability company and an affiliate of Lone Star Funds, a private equity firm, pursuant to the Agreement and Plan of Merger, dated as of December 12, 2021, by and among the company, Merger Sub and Parent. Subject to the satisfaction or waiver of the remaining conditions to closing, the Merger is expected to close in Q2.

16:34 EST Petco to purchase remaining 50% stake in hospital joint venture - Petco has entered into a definitive agreement to purchase Thrive Pet Healthcare's 50% stake in the parties' pet hospital joint venture which currently operates nearly 100 full-service veterinary hospitals in Petco pet care centers across 14 U.S. states, under the THRIVE brand. Petco and Thrive Pet Healthcare formed the strategic joint venture in May 2017. Petco will offer over 800 veterinary care professionals the opportunity to join its network of more than 27,000 Petco employees. Additionally, Petco will transition the nearly 100 THRIVE locations to its Vetco Total Care hospital branding. The transaction is expected to close in Q2, subject to closing conditions.

16:32 EST Cboe Global Markets reports February total options ADV of 13.2M contracts - Total volume across Cboe's four options exchanges was 250.9M contracts, the highest February volume on record.

16:22 EST FleetCor acquires Levarti, terms not disclosed - FleetCor Technologies announced the acquisition of Levarti, an airline software platform company. Levarti provides a suite of solutions that automate passenger disruptions including passenger notifications, flight re-bookings, hotel accommodations, transfers and vouchers. "This acquisition gives us a complementary solution to further automate and streamline passenger disruption events for our airline clients. We expect our combined offering will be of great interest to airlines, and lead to accelerated sales in our lodging airline segment," Ron Clarke, chairman and chief executive officer, FLEETCOR Technologies, Inc.

16:17 EST Broadcom CEO says 'strong enterprise demand' in Q1 - "Broadcom's record first quarter results were driven by strong enterprise demand, and continued investments in next generation technology by hyperscale and service providers," said Hock Tan, President and CEO of Broadcom. "Our second quarter outlook projects year-over-year growth to accelerate." "Consolidated revenue grew 16% year-over-year to a record $7.7 billion and operating profit increased 23%," said Kirsten Spears, CFO of Broadcom. "We generated $3.4 billion in free cash flow and are expecting free cash flow to remain strong in the second quarter. Consistent with our commitment to return excess cash to shareholders, we returned $4.5 billion to shareholders in the quarter including $1.8 billion of cash dividends and $2.7 billion of share repurchases."

16:13 EST Evolus CFO Lauren Silvernail retires - Evolus announced that after nearly four years with the company, Lauren Silvernail will retire from her position as CFO and Executive Vice President of Corporate Development effective May 31, 2022. The search for her successor is already underway.

14:40 EST Indonesia Energy Corporation Limited trading resumes

14:35 EST Indonesia Energy Corporation Limited trading halted, volatility trading pause

13:56 EST Twitter to reopen offices March 15, employees to be allowed to work remotely - Twitter will reopen its offices in the middle of this month, though employees will still be allowed to work remotely, according to an email from CEO Parag Agrawal to staffers. "It's been almost two years since we closed our offices and travel and I'm excited to announce that we're ready to fully open up business travel and all our offices around the world!" Agrawal wrote in a note that he posted to Twitter on Wednesday. He added that "Business travel is back effective immediately, and office openings will start on March 15." Reference Link

13:32 EST Renovare Environmental to acquire Harp Renewables for $20M in cash and stock - Renovare Environmental announced it has entered into a definitive agreement to purchase Harp Renewables and its affiliate, Harp Electric Engineering, for $20M, comprised of $15M of common stock and $5M of cash. "Through this acquisition, Renovare will become the premier provider of Digesters across North America and Europe, allowing the Company to lead the way in reducing harmful emissions from the disposal and land-filling of food and organic waste. Harp Renewables, based in Ireland, is a global leader in thermophilic aerobic digestion and waste treatment solutions. Harp manufactures and sells a wide range of proprietary bio-digesters that convert food and other organic waste into a nutrient-rich, dry, safe soil product that can be used as a fertilizer, soil amendment or soil additive. Harp provides an innovative solution that provides soil regeneration, and significantly reduces the emission of CO2 and greenhouse gases. Harp Electrical Engineering has been operating since 2002 with extensive experience in large scale waste management projects across the globe. Upon closing, Harp will nominate two representatives to the Renovare Board of Directors," the company stated. This transaction, which was unanimously approved by the Boards of Directors of both companies, is expected to close in the first half of 2022, subject to satisfaction of closing conditions, including obtaining the approval of Renovare's shareholders, obtaining financing of the acquisition cash and other customary closing conditions.

13:01 EST Rhythm Energy launches EV energy plan in partnership with EVgo - Rhythm Energy, the Texas-based renewable energy provider, announced the launch of its new Simply Drive energy plan in partnership with EVgo. Texans who sign up for Rhythm's Simply Drive plan support renewable energy production through their home energy choice and with $100 in charging credit for on-the-go charging on EVgo's network powered by 100% renewable electricity. "The transportation market is electrifying at a rapid pace, especially in Texas," said P.J. Popovic, CEO of Rhythm Energy. "Charging electric vehicles with renewable energy is good for wallets, lifestyles and the planet. With Rhythm's Simply Drive plan, consumers will get a 100% renewable energy plan that powers their home and charges their EV affordably, as well as $100 in charging credits with EVgo, so they can extend their zero emission driving when they are away from home. We're proud to bring this plan to market in support of Texans who have made the choice to use electric vehicles. This plan and our partnership with the team at EVgo reflects our commitment to make every aspect of our consumers' energy life easier and cleaner."

12:17 EST Edwards invests in Arizona manufacturing facility - Edwards announced its investment in a new state-of-the-art manufacturing facility in Chandler. The new 200,000-square-foot facility will leverage the latest manufacturing and digital technologies to support the fast-growing North American semiconductor market with services and solutions for the efficient and environmentally sustainable production of chips. The Chandler facility will also feature warehousing facilities, factory areas, meeting rooms, and a dedicated training centre. It is anticipated that the new facility will create approximately 200 new jobs in the local area, with scope to grow along with the market. Construction of the new site in Chandler is underway and from the third quarter of this year, the facility will commence the remanufacturing and assembly of equipment essential to meet the demand for new semiconductor fab requirements. The purchase price of Edwards' investment in the new facility is not disclosed.

12:06 EST Verizon expects 150,000 net additions for fixed wireless in Q1 - The company said, "The expansion of Verizon's C-Band coverage provides additional growth opportunities in nationwide broadband with over 150,000 net additions expected for fixed wireless access alone in the first quarter of 2022. As the company continues to expand its 5G network over the next few years, it plans to: Significantly expands its fixed wireless coverage of households and businesses, disrupting an existing market and capturing share; becoming its second largest contributor to revenue growth. Cover 50 million households and 14 million businesses, and have 4 to 5 million total fixed wireless subscribers by year end 2025."

12:04 EST Verizon announces launch of '+play' platform - Verizon (VZ) announced that its customers will have exclusive access to "+play," which it calls a "groundbreaking platform that allows users to discover, purchase and manage some of their favorite subscriptions across entertainment, audio, gaming, fitness, music, lifestyle and more - all in one place." Through new partnerships with Netflix (NFLX), Peloton (PTON), Live Nation's (LYV) Veeps and services like Disney+ (DIS), discovery+ (DISCA), A+E Networks, AMC+ (AMCX) and others, the hub will "give Verizon customers a simple and efficient way to access and take advantage of exclusive deals for content services," the company said. Verizon added: "+play is a unique digital hub designed to centralize subscription services at no additional cost to Verizon customers. Trials for +play will begin at the end of March with a select group of customers and brands, with an expected consumer launch later this year."

12:03 EST Verizon announces +play direct-to-consumer platform - Verizon announced +play, exclusive to Verizon customers. This unique, direct-to-consumer platform allows users to discover, purchase and manage some of their favorite subscriptions across entertainment, audio, gaming, fitness, lifestyle and more - ALL in one place. +play builds on the content Verizon already offers through leading providers including Disney+, Hulu, ESPN+, discovery+ and AMC+, all of whom are featured in the new service, and introduces new partners, including Netflix, Peloton, Live Nation's Veeps, WW International, Inc., A+E Networks, The Athletic, Calm, Duolingo, and TelevisaUnivision's Vix+, among many others. Limited trials of +play will begin at the end of this month with an expected commercial launch later this year. Verizon expects the product to generate significant new revenues from subscription purchases, increase customer loyalty and improve its market-leading retention rates.

12:02 EST Verizon expects 175M people to be covered with 5G Ultra Wideband by year-end - Verizon Communications announced an acceleration in availability of 5G Ultra Wideband network to an expected 175 million people by year-end 2022. The company said, "This new fast tracked timeline is made possible by the incredible pace of deployment achieved by Verizon's network engineering team. At the company's Investor Day 2022, the leadership team outlined its vision and strategy, powered by its leading 5G network and the source for the company's growth over the next several years. As the world continues to transition to a more hybrid work environment and is increasingly mobile, the new currency will be ultra-fast, ultra-reliable connectivity, creating new markets and ushering in the 5G economy. The company's Network-as-a-Service strategy was built to drive the 5G economy through an ever-expanding volume of services and technologies that are enabled by 5G Ultra Wideband's capacity to connect to a massive number of devices at high speed. The company outlined multiple paths to growth: 5G Mobility, Nationwide Broadband, Mobile Edge Compute and business solutions, the Value Market and Network Monetization, stating expectations that it will drive 4 percent service and other revenue growth for the company in 2024 and beyond."

12:00 EST Veeva falls -17.2% - Veeva is down -17.2%, or -$39.77 to $190.85.

12:00 EST Rush Street Interactive falls -21.3% - Rush Street Interactive is down -21.3%, or -$2.16 to $8.00.

12:00 EST Pure Storage rises 17.1% - Pure Storage is up 17.1%, or $4.54 to $31.04.

11:38 EST CD Projekt halts all sales of its games to Russia, Belarus - Poland-based CD Projekt, the game publisher behind "Cyberpunk 2077" and the "Witcher" titles, said it has decided to halt all sales of its games to Russia and Belarus in light of the Russian military invasion of Ukraine. "Today, we begin working with our partners to suspend digital sales and cease physical stock deliveries of CD PROJEKT Group products, as well as all games distributed on the GOG platform, to the territories of Russia and Belarus," the company said. Reference Link

11:18 EST Accenture to discontinue business in Russia - The company said, "Accenture stands with the people of Ukraine and the governments, companies and individuals around the world calling for the immediate end to the unlawful and horrific attack on the people of Ukraine and their freedom. Therefore, Accenture is discontinuing our business in Russia. We thank our nearly 2,300 colleagues in Russia for their dedication and service to Accenture over the years. We will be providing support to our Russian colleagues. While Accenture does not have a business in Ukraine, we will continue our efforts to help our Ukrainian colleagues working around the globe at Accenture and their extended families; we are providing telehealth for those in Ukraine, and helping resettle family members who leave Ukraine."

10:50 EST WWE shuts down WWE Network in Russia, terminates broadcast partnership - WWE released the following statement: "WWE has terminated its partnership with Russian broadcaster Match and shut down WWE Network in Russia effective immediately. The move eliminates access in Russia to any WWE programming, including the company's weekly Raw, SmackDown and NXT shows, its on-demand library, and all of its premium live events, including WrestleMania 38."

10:37 EST Honeywell sees repurchasing at least $4B of shares in 2022

10:31 EST ArcelorMittal halts production at Ukrainian steelmaking operations - ArcelorMittal confirms that it has taken the decision to idle its steelmaking operations in Kryvyi Rih, Ukraine in order to ensure the safety and security of our people and assets. The company has been evaluating the situation on a daily basis and production had previously been reduced with the plant operating at a technical minimum, it said in a statement. The company added: "The process to idle all blast furnaces has commenced today. The process to safely idle these assets while maintaining asset integrity will take between seven and ten days. ArcelorMittal is deeply concerned about the situation in Ukraine and the threat to our employees and the entire Ukrainian population."

10:16 EST DraftKings raises long-term adjusted EBITDA outlook to $2.1B before deal synergy - DraftKings (DKNG) hosted a virtual Investor Day that began at 9:00 a.m. EST, at which the company presented and distributed to the investment community a slide presentation that stated in part that the company is increasing its long-term adjusted EBITDA estimate to $2.1B before Golden Nugget Online (GNOG) synergies, Marketplace, Media and any other new initiatives. The company's slide said the total addressable market, or TAM, is "larger than we thought" for both online sports betting, or OSB, and iGaming and DraftKings is increasing its total North America TAM estimate to $80B from $67B. The company adds in the slides that its new verticals are off to a "strong initial start" and it expects them to be contribution profit positive in FY22, "validating our thesis of LTV/CAC flywheel." Reference Link

10:04 EST CyrusOne closes Houson asset divestiture - CyrusOne announced that it has closed the previously announced sale of its four Houston data center assets to DataBank Holdings Ltd. Additionally, CyrusOne will lease the Houston West III shell to support a lease signed with a hyperscale customer. Total consideration for the transaction is approximately $670M, subject to a net working capital adjustment. "We are excited to close this transaction as we execute on our capital recycling initiative to fund our continued growth," said David Ferdman, Interim President & CEO. "We are pleased to partner with the DataBank team, and this divestiture further optimizes our portfolio as we redeploy capital into accretive developments across core markets." DH Capital, LLC and DLA Piper LLP served as CyrusOne's exclusive financial and legal advisors, respectively, on the transaction.

10:03 EST United Airlines introduces 'Bag Drop Shortcut' service - United introduces bag drop shortcut, a new, simple way for customers to skip the line, check their bag in a minute or less on average, and get to their flight. According to recent customer surveys, the bag check process can be one of the more stressful and time-consuming parts of the travel experience and United is the first airline to streamline the process in this way.

10:00 EST Rush Street Interactive falls -21.2% - Rush Street Interactive is down -21.2%, or -$2.15 to $8.01.

10:00 EST Cedar Realty Trust rises 14.5% - Cedar Realty Trust is up 14.5%, or $3.62 to $28.50.

10:00 EST Ultrapetrol rises 97300.0% - Ultrapetrol is up 97300.0%, or $48.65 to $48.70.

09:47 EST Rush Street Interactive falls -15.6% - Rush Street Interactive is down -15.6%, or -$1.58 to $8.57.

09:47 EST Cedar Realty Trust rises 14.8% - Cedar Realty Trust is up 14.8%, or $3.67 to $28.55.

09:47 EST Ultrapetrol rises 97300.0% - Ultrapetrol is up 97300.0%, or $48.65 to $48.70.

09:40 EST CMC Materials shareholders approve merger with Entegris - CMC Materials (CCMP) announced that at a special meeting, its stockholders voted to approve the previously announced merger agreement, under which Entegris (ENTG) will acquire CMC Materials in a cash and stock transaction with an enterprise value of approximately $6.5B at announcement.

09:34 EST cbdMD announces expansion in product offerings at GNC - cbdMD has announced an expansion in product offerings online and in over 840 retail GNC Holdings stores nationwide. "cbdMD first partnered with GNC in August 2020, and included a roll-out of three topical SKUs at under 100 retail stores nationwide. Due to consumer receptivity and overall purchasing performance, cbdMD is adding an additional 11 SKUs, available online and at over 840 retail stores across the country. The expansion of product offerings includes a variety of ingestibles: functional CBD gummies, sleep aids, softgels and tinctures. Topical products will continue to be available for purchase both online and in-store. Along with the product and store expansion, cbdMD acquires a more visible footprint at both online and retail store locations, positioning products alongside other daily health and wellness options for consumer consideration," the company stated in a press release.

09:29 EST MiNK Therapeutics announces patients dosed with AgenT-797 iNKT cell therapy - MiNK Therapeutics announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial. In the ongoing clinical trials, it has been demonstrated that AgenT-797 can be administered tolerably in up to 1 billion cells per dose without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity. Pre-clinical data has demonstrated the persistence, trafficking, and anti-cancer activity of AgenT-797, in both solid and liquid cancers. This phase 1, open-label study is evaluating the safety, tolerability, and preliminary clinical activity of AgenT-797, an unmodified, allogeneic iNKT cell therapy, alone and in combination with approved immune checkpoint inhibitors in patients with relapsed/refractory solid tumors.

09:26 EST Alkaline Water teams with Columbia Distributing to sell Alkaline88 in Pacific NW - The Alkaline Water Company and the Clean Beverage company, announced that it has partnered with Columbia Distributing to market, sell, and distribute Alkaline88 to convenience stores and other retailers throughout Washington, Oregon, and Idaho. "Alkaline88 is proud to partner with Columbia Distributing and we look forward to a long and prosperous relationship," said Ricky Wright, President and CEO of The Alkaline Water Company. "Columbia is the premier Direct-Store-Delivery, DSD, in the Northwest and services 20,000 accounts throughout Washington, Oregon, California, and Idaho. This agreement will be key to gaining market share in the great Northwest. Our recent success with other DSD partners in Arizona and Nevada showed us the importance of the DSD model in certain channels and markets. The timing also couldn't be better as we will be opening a new copacker in the Northwest some time in the first quarter. This plant will help us meet the increased regional demand that we expect from our DSD rollout. We look forward to serving our Deliciously Smooth(TM) Alkaline88 to millions of new health-conscious consumers in the Northwest."

09:23 EST Verizon CEO sees 4% revenue growth starting in 2024

09:22 EST E2open acquires e-commerce shipping firm Logistyx for $185M - E2open Parent Holdings has acquired Logistyx Technologies, global parcel and e-commerce shipping and fulfillment technology. company With the combination, E2open enhances its global footprint for multi-carrier e-commerce shipment management, offering companies a complete range of shipping capabilities needed to scale and respond to growing market needs. "The Logistyx team is thrilled to combine with E2open to enable more companies to ship smarter and benefit from the largest supply chain platform and network available," said Geoffrey Finlay, chief executive officer at Logistyx. "We provide our customers, which include top retailers, manufacturers and logistics providers, the automation, visibility and flexibility needed to simplify global fulfillment and compete in an omnichannel world - all within a one-stop, connected platform." The Logistyx combination with E2open accelerates subscription revenue growth and unlocks strategic benefits for clients, including: Increased reach as a global leader in transportation management for parcel shipping: Logistyx's global parcel system augments E2open's direct-to-consumer e-commerce offerings, creating a complete global footprint for multi-carrier parcel management. E2open acquired Logistyx Technologies for a total purchase price of $185M including $90M paid in cash at closing and the remaining balance to be paid in two additional installments at 90 days and 180 days post-closing. E2open has the option to finance the remaining payments through cash or a combination of cash and E2open stock issued to sellers, at the company's discretion.

09:19 EST Cue Health expands collaboration with UPMC Children's Community Pediatrics - Cue Health is further collaborating with the University of Pittsburgh Medical Center Children's Community Pediatrics - UPMC CCP -, part of UPMC Children's Hospital of Pittsburgh, Pennsylvania. Cue will expand its distribution of Cue's Health Monitoring Systems and Cue COVID-19 tests to additional pediatric clinics to support testing for even more patients, physicians, nurses, and staff. With over 55 locations and more than 250 pediatric providers throughout western and central Pennsylvania, UPMC CCP offers standard well and sick care, as well as a variety of specialty services. With this expansion, Cue's tests will be integrated in several clinics as part of UPMC CCP's care and treatment.

09:17 EST Inhibrx's INBRX-101 granted FDA Orphan-Drug Designation - Inhibrx announced that the FDA has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD. Alpha-1 antitrypsin deficiency, or AATD, is an inherited orphan disease affecting an estimated 100,000 patients in the United States. AATD is characterized by deficient levels of the AAT protein, which causes loss of lung tissue and function and decreased life expectancy. INBRX-101 is a recombinant human AAT-Fc fusion protein designed to achieve and maintain levels of AAT found in healthy individuals with a favorable safety profile and the potential for once-monthly dosing. Data from the first multiple ascending dose cohort of INBRX-101 at 40 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels with observed trough levels exceeding the goal of the current standard augmentation therapy with plasma-derived AAT. Interim safety data from 24 patients with AATD showed no drug-related severe or serious adverse events. Drug-related adverse events were predominantly mild with a few moderate events, and all were transient and reversible. No signs of neutralizing anti-drug antibodies have been observed.

09:17 EST Oragenics posts SARS-CoV2 vaccine data in bioRxiv - Oragenics announced the posting of a preprint manuscript in bioRxiv. The manuscript, co-authored by Oragenics and its collaborators at Inspirevax and the National Research Council of Canada Human Health Research Centre, is titled "Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters." The studies described in the manuscript evaluated a novel spike protein subunit vaccine formulation, NT-CoV2-1, containing a proteosome-based mucosal adjuvant designed for intranasal immunization. The studies concluded that intranasal formulation induced robust antigen-specific IgG and IgA titers in the blood and lungs of mice. In addition, the formulation was highly efficacious in a hamster challenge model, reducing the viral load below the limit of detection of the assay. In both mice and hamsters, the antibodies had strong neutralizing activity, preventing the cellular binding of the viral spike protein based on the ancestral reference strain and variants of concern. The studies concluded that this intranasal vaccine formulation warrants further development as a novel SARS-CoV-2 vaccine.

09:10 EST Peloton's former CEO John Foley sells 1.92M shares for abotu $50M - Peloton co-founder and former CEO John Foley has sold about $50M in stock to an investment firm backed by Michael Dell, MSD Partners, according to a securities filing. The sale involved about 1.92M shares, the Wednesday filing said.

09:08 EST CleanSpark announces 276 bitcoin produced in February - CleanSpark released its unaudited bitcoin production and operations update for the calendar year-to-date ending February 28, 2022. Bitcoin Production & Operations Update, unaudited: February monthly production: 276 ; Calendar year-to-date production ending February 28: 581 ; Total BTC holdings as of February 28: 494 ; Total BTC converted for operations and growth in February: 253 ; Currently deployed fleet of over 22,000 latest-generation bitcoin miners with a total hashrate of 2.2 EH/s. The Company fully funded growth and operations through the sale of 253 bitcoins in February 2022 at an average of approximately $39,740 per BTC. Sales of BTC equated to proceeds of approximately $10.1 million, most of which was used for growth capital expenditures at the company's Norcross facility. February daily BTC production reached a high of 10.15.

09:07 EST CPI Aerostructures receives $4M contract from Collins Aerospace - CPI Aerostructures (CVU) announced that Collins Aerospace, a unit of Raytheon Technologies (RTX), has awarded CPI Aero a purchase order to manufacture the Tactical Synthetic Aperture Radar, TacSAR, intelligence, surveillance and reconnaissance, ISR, system. Under a previous contract with Collins, CPI Aero used Collins' design to create fabrication drawings, assembly drawings, parts lists, interface drawings, tooling drawings and other documentation sufficient for the manufacture of the complete TacSAR pod. Under this new contract, CPI will complete non-recurring engineering and tool development and build one prototype pod that Collins will use to complete required test and evaluation of the TacSAR system. In service, Collins intends for the TacSAR system to complement another Collins reconnaissance system, the DB/MS-110, to provide all-weather ISR capability to allied foreign militaries. CPI Aero is a manufacturer of the DB/MS-110 pod for Collins and the TacSAR and DB/MS-110 pods share common structural components.

09:07 EST Kulicke & Soffa increases share repurchase authorization by $400M - Kulicke and Soffa increased its current share repurchase program by an additional $400M to $800M and extended its duration by three years. With this increase and extension, the current repurchase program has a remaining $492.2M authorization available and will expire on August 1, 2025. Cumulatively, since August 27, 2014 through March 2, 2022, $407.8M has been deployed to repurchase an aggregate of 20.6 million shares under the current and prior repurchase authorizations. Kulicke & Soffa ended its Q1 on January 1, 2022 with approximately 63.3 million diluted shares outstanding.

09:06 EST Galaxy Gaming, Aruze Gaming partner to launch Bonus Craps - Galaxy Gaming and Aruze Gaming America, Inc. announced that Bonus Craps, is now available on the semi-autonomous craps game, Roll To Win Craps.

09:04 EST WISeKey unveils first NFT from space - WISeKey International Holding unveiled at the Mobile World Congress, an industry first NFT from space featuring authenticated photography in cooperation with Brooke Shields, actor, model, entrepreneur and author. The secure WISe.Art NFT, powered by Casper blockchain, ensures the integrity of the NFT is protected. The minted NFT of an original photograph from Brooke Shield's personal collection, was sent by a WISeSat space satellite in orbit, following the successful launch and orbit deployment of several WISeSats on the SpaceX Transporter 3 Rideshare mission earlier this year.

09:03 EST Stereotaxis anticipates revenue growth for 2022 - Stereotaxis anticipates revenue growth for the year driven by continued commercial adoption of the Genesis RMN system and stable recurring revenue. System revenue for the year will be primarily recognized in the second half of the year based on current customer schedules. Stereotaxis expects to modestly grow operating expenses with continued investment in key growth drivers, while maintaining a robust balance sheet that allows it to reach profitability without the need for additional financings. Stereotaxis is methodically establishing the product ecosystems that allow for significant future growth in electrophysiology and the broader field of endovascular surgery.

09:01 EST Marvell begins volume shipments of COLORZ II 400ZR modules - Marvell announced that it has begun volume shipments of the Marvell COLORZ II 400ZR module. COLORZ II is the industry's first QSFP-DD pluggable module enabling cloud operators to connect their data centers within a region, with high performance, low power, small form factor 400G coherent transceivers without the need for a separate transport box.

08:44 EST Ouster in strategic customer pact with Third Wave Automation - Ouster announced that it signed a strategic customer agreement with Third Wave Automation, "a provider of versatile and effective autonomous solutions for the material handling industry. The agreement includes a forecast for over five thousand OS sensors through 2025 to equip robotic material handling vehicles with 3D digital lidar, a key component of Third Wave's autonomous driving sensor suite.," said the company in a statement.

08:42 EST Sparta Commercial Services launches crypto payment platform - Sparta Commercial Services announces the launch of SpartaPayIQ, a payment gateway that allows businesses to accept cryptocurrencies. The platform enables businesses to accept Bitcoin, Ethereum, Bitcoin Cash, Litecoin, Dogecoin, and USDT as payment while settling in USD or EUR. Businesses also have the option to keep the cryptocurrency if they don't want to immediately convert it. SpartaPayIQ uses contactless, blockchain-based payment processing technology to instantly convert cryptocurrency payments to USD or other select fiat currencies. This mitigates exposure to market volatility by locking in an exchange rate for fifteen minutes after an invoice is created, guaranteeing that all parties are protected from unpredicted market swings. SpartaPayIQ establishes the Company's entry into the dynamic cryptocurrency space. Sparta plans to unveil another cryptocurrency product in the coming months and SpartaPayIQ will be an integral part of this new product. The platform will also be offered as a payment method on Sparta's other retail sites, including New World Health Brands CBD and Cyclechex.

08:40 EST International Money Express launches digital money remittance app - International Money Express announced the launch of its new, world-class digital mobile money remittance app for both Apple and Android devices, providing customers with safe, easy-to-use features for remitting funds.

08:39 EST Berkeley Lights releases upgrade to Software Suite - Berkeley Lights released an upgrade to its Software Suite including enhancements to Cell Analysis Suite, Image Analyzer, and Assay Analyzer software for the Berkeley Lights Beacon and Lightning Systems. Existing and new features will deliver easier insights, faster throughput operations for antibody discovery, cell line development and cell therapy workflows.

08:37 EST Innovid acquires TVSquared for $100M in cash, 12.5M in stock - Innovid has completed its previously announced acquisition of TVSquared, an independent global measurement and attribution platform for converged TV. "Combining Innovid's expansive ad serving footprint of more than 95 million connected homes, with TVSquared's TV measurement and attribution platform, inclusive of TV viewing and ad occurrence data across millions of households globally, creates an independent, single source of truth for advertisers," the company said. "We believe the combination of independent global ad serving and cross-platform measurement sits at the heart of solving TV measurement's biggest challenges," said Zvika Netter CEO and Co-founder, Innovid. "We've spent over a decade building foundational ad delivery and personalization technology to power TV across channels and devices. Now, together with TVSquared by Innovid, we provide advertisers a complete view of the total TV and digital universe through a scalable, currency-grade measurement platform." Under the terms of the agreement, Innovid acquired TVSquared for $100M in cash and 12.5M in Innovid stock.

08:36 EST Skye Bioscience retains Novotech as CRO for Phase 1 trial of SBI-100 - Skye Bioscience has entered into an agreement with Novotech Health Holdings for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma. Novotech is an internationally recognized full-service biotech specialist CRO known for its experience across the Asia-Pacific region. Novotech will work alongside investigators of the planned study to support aspects of the clinical trial including feasibility assessments, ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, reporting, and project and vendor management. SKYE is actively pursuing a product and clinical development plan with the intent to unlock the full potential of cannabinoids for glaucoma and diseases with significant unmet needs. The company expects to initiate its first-in-human Phase 1 study in Q2-22 with data to be reported in the second half of 2022. Additionally, the Company intends to initiate its proof-of-concept Phase 2 study before the end of the year and will continue to announce its initiatives as they unfold.

08:36 EST Yield10 Bioscience announces update on Camelina line E3902 program - Yield10 Bioscience announced an update on its Camelina line E3902 development program for the purpose of producing low-carbon feedstock oil for the renewable diesel market in the U.S. and Canada. In 2022, the Company plans to continue expanding Camelina line E3092 seed scale up activities, and to advance the field testing of multiple candidate herbicide tolerant Camelina E3902 lines progressing in the pipeline. The Camelina line E3902 has shown a consistent 5% increase in seed oil content as a percentage of seed weight over control plants. In conjunction with developing yield and oil content traits for Camelina, Yield10 is also deploying herbicide tolerance gene traits with a long history of safe use in North America to protect Camelina from weeds and build grower confidence in the crop. "We are focused on leveraging the very promising attributes of our Camelina line E3902 to produce low-carbon feedstock oil for the renewable diesel market," said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. "Camelina is an ideal crop for the large-scale production of feedstocks for renewable biodiesel. We are developing Camelina line E3902 as a spring variety as well as developing two winter varieties to enable production of low-carbon feedstock oil year-round in the U.S. and Canada."

08:34 EST NorthWestern announces Net Zero by 2050 commitment - NorthWestern Corporation d/b/a NorthWestern Energy announces its goal to reach net zero carbon emissions by 2050. "With a foundation that now includes: a company-wide electric generation portfolio that provided approximately 56% of our customers' energy from carbon-free resources in 2021; investments in our natural gas system to reduce methane and carbon emissions; investments in a more efficient, reliable and flexible energy grid; and energy efficiency efforts to reduce customer demand, we believe Net Zero by 2050 is an achievable target," the company said. In the company's natural gas operation it is making investments and operational changes to reduce its methane emission 30% by 2030 from a 2020 base. New technologies and additional pipeline infrastructure investments will be used to achieve Net Zero by 2050. NorthWestern Energy's Net Zero by 2050 commitment is secured by: Existing and future enhancement of its energy efficiency programs and potential demand response options; Investments in a smarter, modernized power grid; Clean electrification of the transportation sector; Employee-initiated sustainable procurement and practice guidelines; Collaborating with communities and stakeholders on strategies for reaching the 2050 net zero emissions goal reliably, safely and affordably; and the conversion of 88,000 street and other lights to LEDs.

08:32 EST Duck Creek Technologies expands collaboration with CoreLogic - Duck Creek Technologies has expanded its collaboration with CoreLogic to help connect critical touchpoints for a seamless underwriting experience. Insurers use CoreLogic's highly accurate and comprehensive risk analytics solutions to help guide smart decision-making. The growing relationship enables customers to obtain a deeper level of business intelligence, one where decisions can be made in real-time.

08:31 EST Alto Ingredients receives additional medical, pharmaceutical certifiactions - Alto Ingredients announced its Pekin, Illinois facility is now ICH Q7 and EXCiPACT Good Manufacturing Practices, GMP, certified. ICH Q7 states that the Alto Ingredients' specialty alcohol is certified for use as an active pharmaceutical ingredient. EXCiPACT GMP certifies for the use of excipients in the pharmaceutical industry; excipients are the inactive components of a drug or medication, such as solvents, carriers or tinctures. Mike Kandris, Alto Ingredients' CEO, said, "We are proud to have earned two certifications in February 2022 for our Alto Pekin facility, augmenting the same two certifications we secured at Alto ICP in February of 2021 and creating redundancy throughout the Pekin campus. Demonstrating our commitment to provide our customers with high quality, reliability, and surety of supply, these certifications are sought-after and valuable market differentiators. They facilitate reporting and maintenance of all the quality aspects required for regulatory purposes for our customers, saving resources, time and money, and when in place, position Alto as a preferred provider. Additionally, these distinctions open doors to new high-quality customers and markets."

08:22 EST Fiserv board elects CEO Bisignano as Chairman, Simons lead independent director - Fiserv announced that its Board of Directors elected Frank Bisignano, President and Chief Executive Officer and a current director of Fiserv, as Chairman of the Board. The board also elected Doyle Simons, a current director, to serve as lead independent director. Both appointments will be effective upon reelection at the Fiserv Annual Shareholders Meeting on May 18. The company also announced that Denis O'Leary, current Chairman of the Board, and Dennis Lynch and Scott Nuttall, current directors, will retire from the board effective after the company's 2022 Annual Shareholders Meeting. "Frank has demonstrated exceptional leadership at Fiserv since his appointment as CEO in 2020, and has built an extremely talented team," said Denis O'Leary, Chairman of the Board. "The board has determined this is the right time for Frank to assume the Chairman role to lead the next phase of the company's innovative transformation and integrated growth strategy." "On behalf of the entire board and management team, I would like to thank Denis O'Leary, Dennis Lynch, and Scott Nuttall for their years of service to Fiserv," said Bisignano. "We are grateful for their valuable insights, guidance and tireless dedication to advancing our company for the benefit of all our stakeholders during their tenure."

08:20 EST StoneCastle board increases quarterly dividend 1c to 39c per share - ArrowMark Financia announced that its Board of Directors increased the quarterly cash distribution to 39c per share from 38c per share, a 1c increase for the first quarter of 2022. The distribution will be payable on March 28, 2022 to shareholders of record on March 21, 2021. "We are pleased to offer our shareholders a dividend increase this quarter. We believe, the dividend increase reflects the Company's ability to consistently over-earn it's declared quarterly dividend rate. ArrowMark Financial is committed to maximizing total risk-adjusted returns and generating long-term value for our shareholders," said Chairman & CEO Sanjai Bhonsle.

08:19 EST Outlook Therapeutics appoints Alicia Tozier as SVP, marketing, market access - Outlook Therapeutics announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access. Most recently, she oversaw commercialization launch efforts for two wet AMD therapies. Outlook Therapeutics expects to submit a Biologics License Application for ONS-5010 ophthalmic bevacizumab with the U.S. Food and Drug Administration during the first quarter of 2022. In anticipation of potential FDA marketing approval in late 2022 or early 2023, Outlook Therapeutics' commercial launch planning includes manufacturing with drug substance manufacturer FUJIFILM Diosynth Biotechnologies and best-in-class drug product manufacturer Aji Biopharma Services, distribution, sales force planning, physician and payor advisory board outreach, key opinion leader support and payor community engagement.

08:18 EST Telus, Samsung announce deployment of MCPTX services in Canada - Samsung Networks and TELUS announced the successful deployment of Canada's first next-generation Mission Critical Push-to-X services. Deployed over TELUS' globally recognized network, this new MCPTX solution will equip Canada's first responders with the information and data they need to more accurately assess emergency situations, improve responsiveness and operational efficiency, and drive better public safety outcomes. This state-of-the-art technology will enhance multimedia communications with vital operational features such as video, geographic information system, geo-fencing, remote database access, and more, keeping communities safer.

08:17 EST Consolidated Communications to sell Kansas City assets to Alinda Capital - Consolidated Communications Enterprise Services has entered into an agreement to sell its Kansas City assets to funds managed by Alinda Capital Partners. The asset sale is an all-cash transaction resulting from the Company's strategic asset review and focus on its fiber expansion plans in its core regions. Consolidated's Kansas City operations includes approximately 19,000 consumer subscribers, 13,000 consumer broadband subscribers, 1,900 commercial subscribers and contributed approximately $50M of revenue in fiscal 2021. The closing of the agreement is subject to closing conditions and customary regulatory approvals, and is expected to be completed in the second half of 2022. The Company will provide more information on the divestiture during its fourth quarter 2021 earnings call on March 3. "We are excited about empowering an experienced management team and dedicated employees in Kansas City to deliver broadband and network solutions to residential, commercial and carrier customers in Kansas City," said Jim Metcalfe, managing partner at Alinda, a specialist in digital infrastructure. "Our mission is to deliver first class service to customers through a locally headquartered and operated company by investing in people, systems, service and the community."

08:15 EST Aemetis closes $100M credit facilities, repays $16M in debt - Aemetis announced the closing of two new, lower interest rate credit facilities with aggregate availability of up to $100 million, comprised of up to $50 million for projects that produce lower carbon intensity renewable products and up to $50 million for working capital. In connection with the closing of the new credit facilities, Aemetis repaid $16 million of higher interest rate debt, building upon the more than $60 million of higher interest rate debt repaid during 2021. The base interest rates under the new credit facilities are 8% for capital projects and 10% for working capital financing and were provided by Third Eye Capital of Toronto, Canada, which has funded Aemetis as a senior lender since 2008. The credit facilities are expected to provide funding for the Aemetis projects that reduce the carbon intensity of renewable fuels, including a zero carbon intensity solar array and extensive process equipment electrification upgrades to the Keyes ethanol plant, a sustainable aviation fuel and renewable diesel plant, and carbon sequestration facilities. Both credit facilities have availability provisions based on the qualified use of funds and other factors. Consideration to the lender includes a warrant to purchase 500,000 shares of Aemetis common stock at a $20 per share exercise price and a warrant to purchase 100,000 shares of Aemetis common stock at an exercise price equal to the 30 day VWAP of Aemetis common stock. The new debt facilities are expected to provide the remaining funding required for engineering and permitting of the Carbon Zero renewable jet and diesel plant in Riverbank, California from Aemetis prior to completion of project debt financing. Aemetis has invested more than $32 million of cash and grants in the renewable jet and diesel plant. In addition to a $3.2 billion, 10-year renewable diesel supply agreement with a leading travel stop company, Aemetis has signed $2.5 billion of sustainable aviation fuel supply agreements with Delta Air Lines, American Airlines and Japan Airlines to supply a 40% blend of SAF and 60% petroleum jet fuel to San Francisco Airport. An additional $1 billion of Memorandum of Understandings have been signed with other members of the oneworld Alliance, which are expected to be converted to signed agreements by the end of Q2 2022.

08:14 EST AMMO CEO says company sees 'serial indications of continued growth' - AMMO issued a letter to shareholders from Fred Wagenhals, Chairman & CEO of AMMO Inc. The letter read in part, " As many of you know, we acquired GunBroker.com in 2021. Today, we find ourselves even more excited about our future together than we were the day we closed on the acquisition. We believed the two Companies shared common values across a wide range of topics, from our Nation's ideals, a shared commitment to democracy and, in particular, our collective unwavering support for the Second Amendment. The Company as now constituted presents the market with an impressive combination of AMMO's technologically innovative manufacturing capabilities and processes with GunBroker.com's online auction marketplace sporting a best-in-class secure transactional technology . The combined enterprise has truly transformed AMMO into a unique opportunity where consumers and investors can find all their shooting needs under one roof, driven by a management team laser-focused on enhancing shareholder value through operational excellence and innovation. Your management team will continue to examine further growth opportunities through acquisition or otherwise in ways that are accretive to our family of companies, align with our shared values, and are best positioned to further enhance shareholder value in POWW and POWWP. As a co-owner in AMMO, you are aware that GunBroker.com has been part of our burgeoning family for more than 10 months and has already significantly contributed to the Company's growth - a trajectory we all work night and day to continue. We recently reported our quarterly financial results on Form 10-Q for the third quarter of our 2022 fiscal year and boasted record net revenues of $64.7 million, including $17.6 million from the Marketplace alone. We grew new users by an average of 55,000 per month and the auction numbers increased 33.45% from the prior year. The GunBroker.com team is now an integral part of the collective AMMO team, thriving in their new home as valued members of the AMMO family. We've made a few other recent announcements I am certain you have read as they have come across the wire - a couple are worth repeating here. First, based upon your Company's solid balance sheet and growing revenues, our Board of Directors recently provided management with an additional tool to increase shareholder value - the authorization to repurchase up to $30 million of AMMO shares. Second, we are proud to have announced that we offered to donate 1 million rounds of ammunition to the Ukrainian Armed Forces in support of their valiant defense against the unprovoked Russian aggression and threat to Ukraine's independence. We are committed to living our values. Within our ammunition and munition components operational unit, the industry remains strong, really constrained only by capacity. Management's long-term strategic growth plans will prove helpful in addressing some of that capacity deficit when we open our new state-of-the-art 160,000 square foot facility in Manitowoc, Wisconsin. Our plan is to continue our 24/7/365 focused efforts with the goal of tripling our ammunition capacity with the well-planned transition into our new plant, estimated to take place in the Summer of 2022. We also see a tremendous opportunity to continue to increase our market share through the GunBroker.com Marketplace and are regularly rolling out initiatives to accomplish that end. We also recently announced that we are reiterating our guidance for the full 2022 fiscal year of approximately $250 million in revenue, an estimated 288% increase over the prior year period, which is projected to include anticipated Adjusted EBITDA of approximately $80 million. Although we remain hyper-focused on today, this week and each quarter, we are always undertaking market analysis and looking ahead - and we see serial indications of continued growth for our business across all sectors and within each business unit. Many of you have heard me say that I am not a patient man, and that applies most directly in my drive to see the AMMO family succeed. The definition of "AMMO Family" to me is the individuals I am pleased to work with, and each of you shareholders that have seen fit to own a piece of this exciting organization."

08:13 EST The Oncology Institute enters into value-based agreement with MaxHealth - The Oncology Institute of Hope and Innovation announced a value-based agreement with MaxHealth to provide medical oncology care to patients in Pinellas and Hillsborough Counties. Starting in the Tampa Bay Area, TOI and MaxHealth intend to expand the footprint of the agreement into neighboring counties in coming months. "We are extremely excited to launch this important partnership with a high-quality primary care organization like MaxHealth," shared Dr. Daniel Virnich, Chief Operating Officer at TOI. "MaxHealth has a reputation for providing outstanding care coordination and services for patients in the counties that they serve, and we believe that our oncology model is ideally suited to extend exceptional care to their patients that require oncology services."

08:11 EST Enphase Energy expands battery storage in Oregon - Enphase Energy announced today that Enphase installers in Oregon have seen growing deployments of the Enphase Energy System, powered by IQ Microinverters and IQ Batteries, after last summer's heatwave left many without power and fueled consumer interest in solar plus battery storage home energy solutions.

08:10 EST Kroger CEO 'confident' in delivering shareholder returns of 8%-11% over time - Chairman and CEO Rodney McMullen said, "Our strategy of leading with fresh and accelerating with digital propelled Kroger to record performance in 2021, on top of record results in 2020. We are incredibly proud of our associates who continue to deliver for our customers through the pandemic. As we look to 2022, we expect the momentum in our business to continue and have confidence in our ability to navigate a rapidly changing operating environment. We are leveraging technology, innovation, and our competitive moats to build lasting competitive advantages. Our balanced model is allowing us to deliver for shareholders, invest in our associates, continue to provide fresh affordable food to our customers and uplift our communities. We remain confident in our growth model and our ability to deliver total shareholder returns of 8% to 11% over time."

08:09 EST I-Mab's TJ-CD4B in gastric cancer granted FDA Orphan Drug Designation - I-Mab announced that the FDA has granted Orphan Drug Designation for TJ-CD4B, a novel Claudin 18.2 x 4-1BB bispecific antibody, for the treatment of gastric cancer including cancer of gastroesophageal junction. TJ-CD4B is the first clinical-stage bispecific antibody that binds to Claudin 18.2-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect. Unlike other therapies involving CLDN18.2, TJ-CD4B has a broader anti-tumor effect covering cancers expressing low levels of CLDN18.2. Preclinical studies have suggested that TJ-CD4B is superior to current CLDN18.2 antibodies and 4-1BB agonistic antibodies due to its stronger anti-tumor activity and a minimal 4-1BB related systemic toxicity. In the ongoing dose-escalation study, TJ-CD4B was safe and well-tolerated at dose up to 3 mg/kg weekly. The company plans to advance the study in biomarker-selected population subsequently.

08:08 EST Aquestive Therapeutics, Haisco enter licensing, supply agreement for EXSERVAN - Aquestive Therapeutics announced the execution of a License, Development and Supply Agreement with Haisco Pharmaceutical Group for Haisco to develop and exclusively commercialize EXSERVAN for the treatment of amyotrophic lateral sclerosis in China. Around 85% of ALS patients suffer from a progressive loss of bulbar functionality. Swallowing food and liquids becomes more difficult over time. While most patients initiate on riluzole, some choose to discontinue treatment at various points in the disease progression due to an inability to swallow a tablet. EXSERVAN is designed to provide a meaningful treatment option, using Aquestive's orally administered PharmFilm dosage form, to patients and caregivers. It alleviates the need for swallowing a tablet and water, while having a negligible impact on volume and viscosity of normal saliva. Pursuant to the agreement, Haisco will lead the regulatory and commercialization activities for EXSERVAN in China. Aquestive will serve as the exclusive sole manufacturer and supplier for the product. Aquestive will receive a $7million upfront cash payment, regulatory milestone payments, and double-digit royalties on net sales of EXSERVAN in China, and will earn manufacturing revenue as the exclusive supplier of EXSERVAN.

08:05 EST E-Home Household Service to launch Digital Human as a Service - E-Home Household Service announced that the Company will debut a Digital Human as a Service that will debut on March 18, 2022 leveraging frontend AI technologies following E-Home's launch of metaverse initiatives. DHaaS features a virtual digital human customer service guide named "Xiao Yi" who provides seamless, 24/7 assistance for household services clients in the Metaverse virtual world. Wenshan Xie, Chairman and CEO of E-Home, commented: "We are very proud to announce another major progress for our Metaverse strategy, which is launched to improve E-Home's operation efficiency and lowers operational costs as standard training and customer services are digitalized in the virtual world and both our staff and customers can access these resources anytime, anywhere on demand. The consumer facing innovation is instrumental in developing and delivering the right technical capabilities to develop and optimize our business operation and diversified household services for our core clients."

08:05 EST IPG Photonics announces continued production at Russia operations - IPG Photonics announced more information regarding its Russian operations in light of current events. IPG's Russian facilities continue to operate and manufacture optical components and finished products for its operations in the U.S., Germany and China. IPG has major production and R&D facilities as well as close to 2,000 employees located in Russia. These facilities supply components that Germany and the U.S. use in production and provides finished products to China and the U.S. In 2021, IPG's Russian operations supplied approximately $100 million of finished product for the Chinese market. Historically, sales to Russian customers have been nominal, totaling $30 million in 2021. Sanctions will increase lead times and shipping costs for components and lasers to and from IPG's Russian operations. As part of contingency planning, IPG already has built several months of critical inventory in Russia to support sales. The Company's Russian facility is currently able to ship optical and other components to IPG affiliates from Russia. In the event that sanctions or other developments resulting from the ongoing Russia-Ukraine war substantially limit IPG's ability to export optical or other components to or from Russia, the Company's sales may be materially impacted. IPG is executing on contingency plans that include increasing manufacturing capacity and inventories of critical components in Germany and the U.S., and qualifying third-party suppliers to reduce reliance on Russian operations. Management believes that the Company can start to reduce the reliance on components sourced from Russia within a few months and substantially reduce the risk related to sourcing these components from Russia in six to nine months. Management continues to assess the impact of the announced sanctions and will monitor any new sanctions. The current cash balance in Russia is less than 1% of total current cash and the Russian operations are self-funding. To preserve cash, IPG also suspended further capital investment in Russia other than for maintenance and non-material items. IPG has no operations in Ukraine.

08:03 EST Magnite's SpringServe unveils BidLink - SpringServe, subsidary of Magnite, announced the launch of BidLink. BidLink is designed to communicate with a publisher's primary ad server to send dynamic programmatic demand insights from integrated video SSPs, enabling competition between traditional-direct and programmatic campaigns. P "We developed BidLink to be the best mechanism for unifying ad decisioning across programmatic and traditional direct-sold deals," said Joe Hirsch, GM of SpringServe. "BidLink provides publishers with an out-of-the-box, fully transparent integration with over 22 SSPs. This gives publishers the opportunity to uplevel their programmatic demand capabilities, whether or not they use SpringServe as their primary ad server."

08:03 EST Poet Technologies launches 400G FR4, 800G Receive Optical Engines - POET Technologies announced the launch of its 400G FR4 and 800G Receive Optical Engines based on the POET Optical Interposer, a unique hybrid silicon photonics platform.

08:02 EST Thorne HealthTech acquires Nutrativa - Thorne HealthTech has acquired Nutrativa, a company leveraging two-dimensional high-speed printing technology to provide alternatives to traditional beverages and gummies via dissolvable supplement discs. Terms of the deal were not announced. The transaction closed on February 28; Nutrativa will now be integrated into Thorne HealthTech. Thorne HealthTech will launch a dissolvable supplement disc product line, beginning with a children's multi-vitamin supplement disc that will provide a high-quality and fuss-free solution for healthy growth and development for children ages four to 12. Through the acquisition, Thorne HealthTech expects to open new target markets. Thorne HealthTech will also seek to expand the 2D technology to large companies interested in private labeling and co-branding.

07:57 EST Recursion provides updated guidance on clinical trial starts - Recursion provided updated guidance on clinical trial starts. Recursion's leadership team has decided that conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest of patients before enrolling infants in a Phase 2 trial of REC-3599 in the ultra-rare indication infantile GM2 gangliosidosis. This decision will delay the GM2 Phase 2 trial start by approximately 2 years. Recursion's Phase 2 trial of REC-994 in Cerebral Cavernous Malformation is on track and we expect to enroll the first patient in the coming weeks. The Phase 2 portion of Recursion's adaptive Phase 2/3 trial of REC-2282 in Neurofibromatosis Type 2 is on track to enroll in Q2. Recursion's Phase 2 trial of REC-4881 in Familial Adenomatous Polyposis is expected to enroll the first patient in either Q2 or potentially Q3, 2022 due to challenges with site opening presented by the Covid-19 Omicron variant. Preparations for Recursion's Phase 1 study of REC-3964 in recurrent C. difficile colitis are on track, and enrollment is expected to begin in the second half of 2022.

07:54 EST CorVel presents Critical Incident Stress Debriefing program - CorVel Corporation presented its Critical Incident Stress Debriefing program, highlighting positive outcomes with the City of Beverly Hills, at the annual Public Agency Risk Management Association meeting on March 1, 2022, in Anaheim, California. Critical incident stress debriefing has been around for over ten years. However, it has recently re-emerged as a tool for employers facing several challenges in our current climate. During the presentation, Tyla A. DiMaria, RN, Case Management Manager for CorVel, discussed the company's patient-centered approach that helps employees who have witnessed a catastrophic or traumatic event process the situation, work through the hurdles and develop coping mechanisms to return to work as quickly as possible. Last year, CorVel's program was expanded to address COVID-19 traumatic stress-a syndrome developing due to the significant mental health challenges associated with the pandemic. During the presentation, DiMaria outlined how the City of Beverly Hills partnered with CorVel to implement a critical incident and COVID-19 traumatic stress debriefing program for city employees, improving return to work and positively impacting overall costs and outcomes.

07:54 EST nCino selected by SmartBank to increase speed, simplify commercial loans - nCino (NCNO) announced that $4B-asset sized SmartBank, a subsidiary of SmartFinancial (SMBK) is moving to the nCino Bank Operating System. SmartBank will utilize nCino's Commercial Banking Solution, which will provide the institution a robust, digitized, end-to-end experience for all its clients. "We know that investing in technology is crucial in the current digital landscape, but it's even more critical to have the knowledge and understanding on where to best allocate that investment. We've been very acquisitive in the market and to ensure that our customer onboarding processes remain as seamless as possible, we needed a best-in-class solution that will serve our clients from anywhere, at anytime," said Daniel Hereford, EVP and Chief Information Officer at SmartBank. "This partnership will create greater efficiency and transparency for our associates and customers, and we look forward to further simplifying the lending experience."

07:53 EST Dyne Therapeutics appoints Incerti to board of directors - Dyne Therapeutics (DYN) announced the appointment of Carlo Incerti, M.D., to its Board of Directors. Incerti is currently an operating partner at Forbion (FRBN), a life sciences venture capital firm.

07:51 EST BridgeBio, Helsinn Group announce update to strategic collaboration - Helsinn Group and BridgeBio Pharma announced an update to their existing strategic collaboration to develop, manufacture and commercialize infigratinib for oncology indications. Under the terms of the amended and restated agreement, Helsinn will gain an exclusive license to commercialize infigratinib in the U.S. and will be responsible for developing, manufacturing and commercializing infigratinib in oncology indications worldwide except for achondroplasia or any other skeletal dysplasias and except in mainland China, Hong Kong and Macau. BridgeBio will be eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn. BridgeBio will retain all rights to develop, manufacture and commercialize infigratinib in skeletal dysplasia, including achondroplasia. In 2021, Helsinn and BridgeBio obtained accelerated approval for TRUSELTIQ from the U.S. Food and Drug Administration for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Additionally, the two parties received conditional approval by Health Canada and provisional approval by the Therapeutics Goods Association in Australia for TRUSELTIQ for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Continued approval in the U.S., Canada and Australia for this indication may be contingent upon confirmatory trials.

07:48 EST CalAmp, Noregon partner to deliver remote diagnostics, predictive maintenance - CalAmp announced its partnership with vehicle data expert Noregon to deliver remote vehicle diagnostics and predictive maintenance capabilities to transportation, logistics and fleet operators. This partnership aims to blend real-time data insights from CalAmp iOn fleet management software, edge computing, and cloud platform services with predictive algorithms in Noregon's TripVision remote diagnostic software to enable preemptive alerts to vehicle issues before critical failures occur. "By integrating TripVision with iOn, operators gain not only a holistic view into their tractors, trailers, and cargo but also advanced vehicle diagnostics to ensure fleet and driver safety, while preventing costly vehicle downtime that can significantly reduce productivity and profitability," the company said. "We are thrilled to work with the vehicle data experts at Noregon and to integrate TripVision's predictive maintenance capabilities with our iOn and edge computing solutions," says Jeff Clark, chief product officer for CalAmp. "Together, we can offer fleet operators unmatched fleet visibility and diagnostic intelligence in one unified view to ensure their trucks maintain optimal performance while enabling operational efficiency and profitability of the entire fleet."

07:47 EST Field Trip Health and Cerebral partner for end-to-end mental health care - Field Trip Health announced a strategic partnership with Cerebral, an online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health's ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. Field Trip Health currently has clinics operating in eight major U.S. cities. With this partnership, Field Trip Health patients will have access to services beyond psychedelic treatments and can now access a holistic offering of mental health treatments through Cerebral.

07:46 EST Veritex commences common stock offering - Veritex Holdings announced that it has commenced an underwritten public offering of shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Keefe, Bruyette & Woods, A Stifel Company and Goldman Sachs & Co. LLC are serving as the joint book-running managers for the offering, and Raymond James & Associates, Inc. is acting as passive book-running manager. The Company intends to use the net proceeds of this offering for general corporate purposes and to support its continued growth, including investments in Veritex Community Bank and future strategic acquisitions.

07:45 EST Medigus announces Agmon-Levin joins Polyrizon's SAB - Medigus announced that Polyrizon, a privately held company in which Medigus owns 37.03%, has added Prof. Nancy Agmon-Levin, expert in immunology, allergy, internal medicine, to its scientific advisory board, SAB. Prof. Agmon- Levin is the Head of the Clinical Immunology, Angioedema and Allergy Unit, Lupus and Autoimmune Diseases Clinic at Sheba Medical Center.

07:43 EST Wave Life Sciences expects cash to fund operations into Q2 of 2023 - Wave expects that its existing cash and cash equivalents will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.

07:39 EST Ceres Acquisition announces extension, amount of redemptions - Ceres Acquisition announced that it has extended the permitted timeline to complete a qualifying transaction to June 30, 2022. The Extension was previously approved at a special meeting of the holders of Class A Restricted Voting Shares of Ceres held on February 23, 2022. Ceres' board of directors have also approved the Extension, which is effective as of March 3, 2022. In connection with the Extension, Class A Restricted Voting Shareholders were provided with the option to redeem all or a portion of their Class A Restricted Voting Shares and an aggregate of 10,677,201 Class A Restricted Voting Shares were deposited and not withdrawn and will accordingly be redeemed. A payment of US$10.00 per redeemed Class A Restricted Voting Share is being made, before taking withholding taxes into account, which includes an aggregate amount of US $30,333.99 being paid to redeeming Class A Restricted Voting Shareholders by Ceres' sponsor, Ceres Group Acquisition Sponsor, LLC, pursuant to the terms of the Make Whole Agreement and Undertaking entered into by the Sponsor with the Corporation on March 3, 2020.

07:35 EST Entasis Therapeutics provides update on upcoming milestones - Phase 3 ATTACK registrational trial for sulbactam-durlobactam achieved all primary and secondary endpoints, NDA submission planned for mid-2022. Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023.

07:34 EST Travelzoo expects return to profitability in Q1 - The company said, "We currently expect substantially higher revenue and a return to profitability in Q1 2022. We continue to see a trend of recovery of our revenue. However, there could be unexpected fluctuations in the short term. During the pandemic, we have been able to lower our fixed costs. We believe we can keep our fixed costs relatively low in the foreseeable future-while revenue is expected to grow."

07:33 EST Alithya Group announces new status as AWS Advanced Tier Services Partner - Alithya Group (ALYA) is proud to announce its new status as an Amazon (AMZN) Web Services Advanced Tier Services Partner, a certification achieved in compliance with the AWS Partner Network program. As a Select Partner since 2019, Alithya has since proven the strength of its technical competencies, as well as the depth of its market penetration potential, in meeting AWS requirements for elevation to Advanced Tier Services Partner status. With access to the full spectrum of AWS cloud-based services and solutions, Alithya's certification opens the door to a broader cloud consulting and solutions implementation offering moving forward.

07:32 EST Nielsen, Cox Media Group announce multi-year renewal agreement - Nielsen and Cox Media Group announced a multi-year renewal agreement for television and audio measurement services covering Cox Media Group local television stations in 10 full service television markets and Cox Media Group local radio stations in 10 full service radio markets. With this agreement, Cox Media Group stations will continue to utilize a comprehensive suite of Nielsen measurement services to demonstrate audience value to advertisers. The agreement also includes CoxReps, a nationwide network of media professionals, which provides television sales representation of broadcasters with a wide network of advertising agencies. Included in the agreement is Nielsen Local Media Impact, which has been licensed by CMG radio stations in Atlanta, Houston, Jacksonville, Fla., Miami, Orlando, San Antonio and Tampa, to help optimize advertising campaigns. CMG radio stations will also have access to the National Regional Database, a customizable tool of radio listening information for every market that Nielsen Audio surveys. The agreement also renews access of CMG radio stations to Nielsen Scarborough, which provides local market research and measures 2,000 market categories. Additionally, the stations will continue to have access to Scarborough MARS Healthcare Module to help maximize advertising strategies for CMG's growing healthcare segment. CoxReps, along with CMG television stations, have also renewed with Nielsen Scarborough.

07:30 EST Fulcrum Therapeutics announces REACH Phase 2 trial of losmapimod - Fulcrum Therapeutics announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with facioscapulohumeral muscular dystrophy, in the second quarter of 2022. FSHD is a serious, rare, progressive and debilitating disease for which there are no approved treatments. It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving the face, scapula and shoulders, upper arms, and abdomen. Impact on patients includes profound decreases in the ability to perform activities of daily living, loss of upper limb function, loss of mobility and independence, and chronic pain. Based on results from a Phase 2b study of losmapimod showing clinical benefit, Fulcrum engaged with U.S. and EU regulatory agencies, including the Food and Drug Administration, and gained alignment on key aspects of the design for a Phase 3 trial. REACH will be a randomized, double-blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. The trial is expected to enroll approximately 230 adults with FSHD. Patients will be randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo, and evaluated over a 48-week treatment period. The primary endpoint of the study is the absolute change from baseline in Reachable Workspace. Secondary endpoints include muscle fat infiltration, Patient Global Impression of Change, and Quality of Life in Neurological Disorders of the upper extremity. REACH will also include patient-centered assessments of healthcare utilization. Results from ReDUX4, a randomized, double-blind, placebo-controlled Phase 2b trial, which enrolled approximately 80 patients treated for 48 weeks, demonstrated clinically relevant benefits on multiple measures of muscle health and function as well as patient-reported outcomes. Notably, losmapimod improved accessible surface area in RWS, a quantitative measure of upper extremity range of motion and function that has shown to correlate with the ability to independently perform activities of daily living. Losmapimod also decreased progression of fat infiltration in muscles already affected by disease and preserved the health of normal-appearing muscles. Additionally, losmapimod-treated patients reported feeling better compared to those on placebo using the assessment. Consistent with losmapimod's extensive safety and tolerability profile from clinical trials outside of FSHD, there were no serious treatment-related adverse events observed in the Phase 2b trial. Fulcrum will host a KOL meeting on Thursday, March 24, 2022 from 10:00am - 12:00pm ET with Nicholas E. Johnson, MD, M.Sci., FAAN, associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at Virginia Commonwealth University and Jay J. Han, MD, professor and vice chair residency program director, University of California, Irvine.

07:28 EST Tela Bio announces US launch of SiteGuard No Rinse Antimicrobial Solution - TELA Bio announced the commercial launch of its SiteGuard No Rinse Antimicrobial Solution for use in plastic reconstructive surgery. "SiteGuard is a complementary technology that we believe enhances our mission to deliver a portfolio of next-generation soft-tissue solutions that are both clinically effective and economically impactful," said Antony Koblish, President and CEO of TELA Bio. "Early test market experience with SiteGuard has been encouraging, and we look forward to broadening awareness and usage of the technology nationwide."

07:27 EST First Wave BioPharma announces poster presentation at DDW 2022 - First Wave BioPharma announced that an abstract entitled, "Niclosamide Enemas, A Safe And Effective Treatment In Mild To Moderate Ulcerative Proctitis/Proctosigmoiditis: Results From An Open Label Study," has been accepted for a poster presentation at the 2022 Digestive Disease Week Conference, DDW 2022. The poster will share data from a Phase 1 open label study of niclosamide as a potential treatment for patients with mild to moderate ulcerative proctitis, UP, and ulcerative proctosigmoiditis, UPS. UP and UPS are two anatomically restricted forms of ulcerative colitis, a chronic inflammatory bowel disease, IBD, consisting of inflammation and ulcers in the colonic mucosal lining of the large intestine. "The research presented by Dr. Monteleone at DDW 2022 is intended to demonstrate the potential of niclosamide as a treatment for UP and UPS and is an important touchstone for our ongoing Phase 2 clinical trial of FW-UP," stated James Sapirstein, President and CEO of First Wave BioPharma. "Our research has demonstrated the potential for niclosamide in UP and UPS, including durable therapeutic effect and clinical remission rates above those reported for the commonly used steroid, budesonide. We look forward to building on this data to illustrate the capabilities of FW-UP and our proprietary niclosamide formulations to provide safe, non-systemic treatments for IBDs and reduce or eliminate entirely the need for steroids and immunomodulators."

07:23 EST Aravive announces updated data, new biomarker data from study of batiraxcept - Aravive announced positive new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer, ccRCC, and new data from a biomarker high subgroup. As of February 4, 2022, 26 ccRCC patients have been treated with batiraxcept at doses of 15 mg/kg and 20 mg/kg, plus cabozantinib 60 mg daily in previously treated, 2L+, patients with ccRCC. Key findings include: No dose limiting toxicities observed at either the 15 mg/kg or 20 mg/kg batiraxcept dose in combination with cabozantinib; At a median follow-up of 4.9 months on February 4, 2022, 92% of patients remain on study; Best overall response rate in the ITT population is 46%; In the 15 mg/kg population, best ORR is 56%; In the 20 mg/kg population, best ORR is 30%; No patient has had progressive disease as their best response; The 6-month progression-free survival rate in the ITT population is 79%; Median duration of response has not been reached; the 3-month DOR is 100%. Among the 26 patients treated in the ccRCC trial, 25 were evaluable for baseline sAXL/GAS6. A high ratio optimized a patient's ability to respond to batiraxcept plus cabozantinib. Key findings from biomarker high patients include: Best ORR rate in the biomarker high population is 63%; In the 15 mg/kg population, best ORR is 75%; In the 20 mg/kg population, best ORR is 43%; The 6-month PFS rate in the biomarker high population is 77%, with a 6-month PFS rate of 91% in the 15 mg/kg biomarker high group; Median DOR has not been reached in the biomarker high subgroup; the 3-month DOR is 100%.

07:21 EST AnPac Bio's Changwei receives apptoval to explore strategic alternatives - AnPac Bio-Medical Science announced that its fully owned biochip subsidiary, Changwei System Technology, was recently evaluated and appraised by China Alliance Appraisal Co. Ltd., an independent company that is certified and licensed by the China Appraisal Society under the Ministry of Finance and is one of the top 10 appraisers in China by revenue. China Alliance Appraisal, Co., Ltd. provided a certified written appraisal report which valued Changwei at RMB 578 million. An appraisal is an opinion about the approximate value of a company and is not a guarantee that any transaction may be completed based on that appraised value or at all. The appraisal was performed following the recent approval from the board of directors of AnPac Bio to explore strategic alternatives for Changwei, including a potential strategic investment, to maximize shareholder value for the Company. Changwei was founded in 2011 and has since focused on the design, R&D, and testing of novel, specialty bio-integrated circuit chips for life science applications. The team consists of a group of IC experts and engineers from IC and IC packaging companies such as Micron Technologies, Motorola, Semiconductor Manufacturing International Corporation, and Amkor. Changwei is currently developing biochips for in vitro diagnostics applications and the biochip currently used in Anpac Bio's Cancer Differentiation Technology platform for cancer screening and detection, which has already been commercialized and is in volume production. In addition, in 2021, Changwei began development of a new biochip for AnPac Bio JV's novel cancer treatment. Recently, Changwei signed a letter of intent with a life science company, under which Changwei will work on a new biochip for an automatic drug injection medical device for diabetes patients.

07:19 EST Tilray announces proposed agreement for strategic alliance with Hexo - Tilray Brands announced proposed agreements for a commercial and financial partnership with HEXO Corp. that would bring together Canada's top two cannabis market share leaders, strengthening their respective positions and setting the stage for increased production efficiencies amid competitive market dynamics. Under the terms of the proposed agreement, Tilray Brands would acquire up to US$211 million of senior secured convertible notes that were issued by HEXO and are currently held by funds affiliated with HT Investments MA. The Notes would be amended to permit Tilray Brands to exercise conversion rights at a price of C$0.90 per HEXO Share and acquire a significant equity ownership position in HEXO, driving meaningful, additional upside and direct participation in HEXO's considerable growth opportunities. The strategic alliance between Tilray Brands and HEXO would provide several financial and strategic benefits, including: Accretion and Flexibility: the acquisition of the Notes by Tilray Brands would be immediately accretive to Tilray Brands. As amended, the terms of the Notes will provide that the Notes shall bear interest at a rate of 10% per annum from the date of closing. During the first year, the interest will be paid in cash and during the remainder of the term, the Notes will be paid half in cash in each year and the remaining half will be added to the principal amount as a payment-in kind when the payments are due and any payments of such PIK will be made in cash at the time of maturity or paid in additional HEXO Shares upon conversion. In addition, Tilray Brands shall have the flexibility to either be paid the principal amount plus any accrued interest and PIK upon the maturity of the Notes or, prior to maturity, convert the principal amount plus any accrued interest and PIK into a substantial ownership position in HEXO. Substantial Synergies: the proposed alliance between Tilray Brands and HEXO is further expected to deliver up to C$50 million of cost synergies, to be shared equally, within two years of the completion of the Transaction. Both companies have been working together to evaluate cost saving synergies as well as other production efficiencies, including with respect to cultivation and processing services, certain Cannabis 2.0 products, including pre-rolls, beverages and edibles, as well as shared services and procurement. Increases Product Breadth and Commitment to Innovation: Tilray Brands and HEXO bring together industry leading expertise in the global cannabis industry, including cannabis cultivation, product innovation, brand building, and distribution. Leveraging both companies' commitment to innovation and operational efficiencies, both companies would share their respective expertise and know-how to strengthen market positioning and capitalize on opportunities for growth through a broadened product offering and accelerated CPG innovation. Upon closing, Tilray Brands will nominate Denise Faltischek to the HEXO Board of Directors, in addition to appointing one Board observer. Under the terms of the Transaction, and subject to negotiation of the definitive documents and the satisfaction of specific conditions, Tilray Brands would acquire 100% of the remaining US$211 million outstanding principal balance of the Notes, all of which were originally issued by HEXO to HTI. As consideration for Tilray Brands' interest in the Notes, Tilray Brands would pay 95% of the then outstanding principal balance for the Notes which includes accrued and unpaid interest on the Notes, as well as other agreed direct and indirect costs incurred by Tilray Brands in connection with the Transaction. Until closing, HTI may continue to redeem the Notes pursuant to their terms; however, in no event shall the outstanding principal balance of the Notes, when ultimately purchased by Tilray Brands, be less than US$182 million. Among the various amendments to be made to the Notes, the initial conversion price would be C$0.90, implies that, as at March 2, 2022, Tilray Brands has the right to convert into approximately 37% of HEXO Shares. The Purchase Price would be satisfied in cash, common shares of Tilray Brands, or a combination thereof, at Tilray Brands' sole discretion. HEXO will not receive any proceeds as a result of Tilray Brands' proposed purchase of the Notes from HTI. In connection with the proposed Transaction, the parties would amend and restate the indenture governing the Notes to, among other things, extend the maturity date by three years, to May 1, 2026; provide for the revised interest amounts previously identified; and amend or eliminate certain affirmative and negative covenants, including as it relates to minimum liquidity and minimum EBITDA covenants. The Notes will also provide Tilray Brands with subscription rights and top-up rights in respect of all future equity and debt issuances by HEXO following closing, other than in respect of certain customary exceptions.

07:17 EST BeiGene says BRUKINSA approved by Health Canada for MZL treatment - BeiGene announced that BRUKINSA or zanubrutinib, has been approved by Health Canada for the treatment of adult patients with marginal zone lymphoma, MZL, who have received at least one prior anti-CD20-based therapy. "We are pleased that BRUKINSA is now approved in its third indication in Canada, R/R MZL, and this terrific milestone was made possible by the participating patients and investigators. This approval further supports our belief that BRUKINSA is a potentially best-in-class BTK inhibitor, with the MAGNOLIA trial results in R/R MZL providing additional evidence that the selective design of BRUKINSA can be translated into improved treatment outcomes," said Jane Huang, M.D., Chief Medical Officer of Hematology at BeiGene. "We will continue to work with physicians and their patients as part of our broad global clinical program for BRUKINSA, which includes 35 trials and more than 3,900 subjects across 28 markets." "BRUKINSA is a highly selective next-generation BTK inhibitor designed to improve tolerability by minimizing off-target binding. In clinical trials, BRUKINSA achieved a high overall response rate among relapsed/refractory MZL patients and was generally well-tolerated. With this approval, Canadian patients with R/R MZL will have the option to receive BRUKINSA monotherapy as a treatment and a new hope for improved treatment outcomes," said Dr. Anthea Peters, a hematologist at the Cross Cancer Institute in Edmonton, Alberta.

07:16 EST Tonix Pharmaceuticals announces FDA Orphan-Drug Designation for TNX-2900 - Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi syndrome. "Orphan-Drug Designation by the FDA is an important milestone and further validates our efforts to investigate the utility of TNX-2900 for Prader-Willi syndrome," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "It underscores the urgent, unmet medical need for patients diagnosed with this disease, and will benefit us as we continue to advance our program."

07:15 EST Old Dominion reports revenue per day increased 38.3% in February vs. last year - Old Dominion Freight Line reported certain less-than-truckload operating metrics for February 2022. Revenue per day increased 38.3% as compared to February 2021 due to an 18.3% increase in LTL tons per day and an increase in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 19.8% increase in LTL shipments per day that was partially offset by a 1.3% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 16.8% and 10.7%, respectively, as compared to the same period last year. Greg C. Gantt, President and Chief Executive Officer of Old Dominion, commented, "Old Dominion's revenue growth for the first two months of the quarter reflects our ongoing ability to win market share while also improving our yield. Demand for our superior service, as well as the domestic economy, both remained consistently strong. We expect these favorable trends to continue and, as a result, we remain committed to further expanding the capacity of our people, our fleet, and our service center network to support anticipated growth this year. The combination of these ongoing investments and our ability to deliver superior service at a fair price continue to form the foundation of our long-term strategic plan. As we continue to execute on the fundamental elements of this plan, we remain confident in our ability to produce further profitable growth and increase shareholder value."

07:13 EST Grab Holdings sees Q1 mobility GMV to be between $750M-$800M

07:11 EST Grab Holdings sees Q1 deliveries GMV to be between $2.4- $2.5B

07:10 EST Fulcrum Therapeutics expects cash to fund requirements into 2024 - As of December 31, 2021, cash, cash equivalents, and marketable securities were $218.2 million, as compared to $112.9 million as of December 31, 2020. Based on current plans, the company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2024.

07:09 EST Hut 8 Mining provides production update for February - Hut 8 Mining achieved record Bitcoin holdings in the period ending February 28. Production highlights for February 2022 include: 289 Bitcoin were mined, resulting in an average production rate of 10.3 Bitcoin per day; Ethereum mining - paid in Bitcoin - generated approximately 14% of total production, at an average cost of less than C$2,600 per Bitcoin; 100% of the self-mined Bitcoin for February were deposited into custody, consistent with Hut 8's HODL strategy; total Bitcoin balance held in reserve is 6,115 as of February 28; installed operating capacity currently sits at 2.5 EH/s, a 5% increase from January 31; installed 2,715 MicroBT M30S and M31S+ miners; construction at Hut 8's third mining facility located in North Bay, Ontario continues to advance.

07:05 EST Lumentum raises share repurchase authorization to $1B - Lumentum Holdings announced that its Board of Directors has authorized an increase of its share repurchase program to $1B which is currently underway and will now expire in May 2024. This supersedes the previous share repurchase program of $700M over two years that was announced in May 2021.

07:05 EST Passage Bio announces anticipated upcoming milestones - Anticipated Upcoming Milestones: Dose first patients in Phase 1/2 studies for Krabbe disease and FTD-GRN in early 2022. Additional clinical data milestone timing to be provided following dosing of first patients. Submit Investigational New Drug application for Phase 1/2 clinical program for PBML04 in mid-2022. Present interim safety and biomarker data for Cohorts 2 and 3 for Imagine-1 clinical trial for GM1 in 2H 2022. Advance pipeline programs for amyotrophic lateral sclerosis, Charcot-Marie-Tooth Type 2A, Parkinson's disease, Canavan disease and Huntington's disease. Evaluate new product candidate programs with GTP to continue to expand pipeline in 2022. Operationalize new pilot manufacturing suite by year-end 2022 at the Princeton West Innovation Campus in Hopewell, N.J., for scale-up capability to support R&D pipeline as well as future development plans.

07:03 EST One Rock Capital to acquire Therm-O-Disc from Emerson, terms not disclosed - One Rock Capital Partners announced that one of its affiliates has entered into a definitive agreement to acquire Therm-O-Disc, a subsidiary of Emerson. Therm-O-Disc is a designer and manufacturer of safety-critical sensors, thermal cutoffs and sealed connecting components primarily used in heating, ventilation and air conditioning, appliance, water heater, industrial, aerospace & defense, and transportation applications. Headquartered in Mansfield, Ohio, Therm-O-Disc has over 4,000 employees globally. Completion of the transaction, which is expected in the first half of 2022, is subject to applicable regulatory approvals and customary closing conditions.

06:53 EST Pentair sees 25c of adjusted EPS accretion in 2023 from Manitowoc Ice deal - Pentair plc (PNR) announced that it has entered into a definitive agreement to acquire Manitowoc Ice, a portfolio brand of Welbilt, Inc. (WBT) and provider of commercial ice makers, for $1.6B, subject to customary adjustments. When adjusted for approximately $220M of expected tax benefits, the net transaction value is approximately $1.38B. The deal is expected to add about 25c of adjusted EPS accretion in 2023 and about 40c in 2025. Adjusted EPS accretion is expected in 2022 based on anticipated acquisition closing timing. The company sees an expected EBITDA margins of 30%+ for Manitowoc Ice, "significant revenue synergies, and accelerated deleveraging based on strong free cash flow," Pentair added.

06:49 EST Pentair to acquire Manitowoc Ice from Welbilt for $1.6B - Pentair plc (PNR) announced that it has entered into a definitive agreement to acquire Manitowoc Ice, a portfolio brand of Welbilt, Inc. (WBT) and provider of commercial ice makers, for $1.6B, subject to customary adjustments. When adjusted for approximately $220M of expected tax benefits, the net transaction value is approximately $1.38B. Pentair expects to fund the acquisition with new debt that is anticipated to be investment grade. Subject to customary closing conditions and necessary regulatory approvals, the transaction is expected to close in the second quarter of 2022. "With a global installed base of approximately 1 million units and more than 200 models of commercial ice machines worldwide, Manitowoc Ice has excelled at delivering differentiated product innovation, food safety and sustainability in icemaking. Manitowoc Ice employs more than 800 team members and operates facilities in Manitowoc, Wis., Monterrey, Mexico and Hangzhou, China. Manitowoc Ice generated $308 million in revenue in 2021 with EBITDA margins of approximately 30%," the company said. "We expect this strategic acquisition to be a game changer for our commercial water solutions platform, establishing a differentiated, total water management offering and expanded network within the foodservice industry. Manitowoc Ice's industry-leading global positions in an incredibly attractive industry, coupled with its strong track record of profitable growth and culture of innovation and sustainability are expected to further establish Pentair as a leader in a vast and growing industry. At Pentair, we have remained steadfast in our commitment to developing tailored, sustainable solutions that bring water to life through effortless user experiences. We believe Manitowoc Ice's culture and priorities are highly aligned with this mindset through value-added solutions that are centered on its customers' needs. With the addition of Manitowoc Ice, we expect Pentair will have the opportunity to bring to our customers a total water management solution that optimizes complementary portfolios through a large installed customer base in foodservice. Further, it will provide an additional growth engine for Pentair that augments our leading industry positions and innovative offerings, ultimately positioning us well for long-term value creation for our stakeholders," said John Stauch, Pentair President and CEO.

06:42 EST ViewRay announces Acibadem Group purchases second MRIdian system - ViewRay announced that the Acibadem Group has purchased a second MRIdian MRI-guided radiation therapy system for installation at the Acibadem Altunizade Hospital in Istanbul, Turkey.

06:40 EST Sotherly Hotels sees Q1 composite RevPAR down 20% vs. 1Q19

06:38 EST Bluegreen Vacations authorizes additional $50M share repurchase program - Bluegreen Vacations announced that its Board of Directors has expanded the company's share repurchase program by authorizing the repurchase of an additional $50M of shares of the company's Class A and Class B Common Stock. Based on the Board's expansion of the program, approximately $62.7M will be available for repurchasing shares in the future.

06:12 EST Tesla's Musk invites UAW to hold vote at Tesla California factory - Tesla CEO Elon Musk invited the UAW to hold a vote at the company's California factory. In a tweet, Musk said: "Our real challenge is Bay Area has negative unemployment, so if we don't treat and compensate our (awesome) people well, they have many other offers and will just leave! I'd like hereby to invite UAW to hold a union vote at their convenience. Tesla will do nothing to stop them." Reference Link

06:11 EST Quhuo receives Nasdaq non-compliance notice - Quhuo received a notification letter dated March 1 from the Listing Qualifications Department of The Nasdaq Stock Market, indicating that the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules as the closing bid price of the company's American depositary share has been below $1.00 per ADS for a period of 30 consecutive trading days. The Notification Letter has no immediate impact on the company's listing on the Nasdaq Capital Market. The company has a compliance period of 180 calendar days, or until August 29, to regain compliance with Nasdaq's minimum bid price requirement. If the company does not regain compliance by August 29, 2022, the Company may be eligible for additional time to regain compliance or may face delisting. The company is considering its options, including an adjustment of its ADS-to-Class A ordinary share ratio, to regain compliance with the minimum bid price requirement.

06:09 EST Biodesix's PIR test shows predictive efficacy in lung cancer - Biodesix announced impactful data on the Primary Immune Response - PIR - test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. The data showed that the Biodesix PIR test was predictive for survival outcomes when tested at baseline or 3 weeks after immune checkpoint inhibitor - ICI - treatment initiation. Furthermore, the data suggested that patients classified as PIR-Resistant were more likely to experience rapid onset of immune related adverse events when treated with ICIs. "This data is meaningful for patients with non-small cell lung cancer who are being considered for treatment with ICIs. Immune Checkpoint inhibitor drugs have gained interest in oncology because of their ability to boost a person's immune response against cancer cells. It was recently estimated that nearly half of US patients with cancer are eligible for ICI therapy, however only about 1 in 8 will respond," said CEO Scott Hutton. "Developing tools that provide a better understanding of a patient's likely overall outcome and adverse events prior to treatment with ICIs will be critical for both the physician and patient, which is the true benefit of the PIR test." While the PIR test is not yet commercially available, it is being studied further in multiple ongoing clinical studies and is expected to launch commercially in 2023.

06:05 EST Sprague Resources still sees 2022 adjusted EBITDA $105M-$120M

05:40 EST Sanmina, RSBVL to create manufacturing joint venture in India - Sanmina and Reliance Strategic Business Ventures, or RSBVL, a wholly-owned subsidiary of Reliance Industries, India's largest private sector company, announced that they have entered into an agreement to create a joint venture through an investment in Sanmina's existing Indian entity. The day-to-day business will continue to be managed by Sanmina's existing management team in Chennai. The joint venture will create an electronic manufacturing hub in India, in line with the Hon'ble Prime Minister's "Make in India" vision. The joint venture will prioritize high technology infrastructure hardware, for growth markets, and across industries such as communications networking, medical and healthcare systems, industrial and cleantech, and defense and aerospace. In addition to supporting Sanmina's current customer base, the joint venture will create a 'Manufacturing Technology Center of Excellence' that will serve as an incubation center to support the product development and hardware start-up ecosystem in India. RSBVL will hold 50.1% equity stake in the joint venture entity with Sanmina owning the remaining 49.9%. RSBVL will achieve this ownership primarily through an investment of up to Rs 1,670 crore in new shares in Sanmina's existing Indian entity, while Sanmina will contribute its existing contract manufacturing business. As a result of the investment, the joint venture will be capitalized with over $200M of cash to fund growth.

05:29 EST RYB Education to divest directly operated kindergarten business, change name - RYB Education announced that its subsidiaries have entered into termination agreements with certain variable interest entities. By entering into those termination agreements, RYB will no longer have contractual control over its directly operated kindergarten business. The divesture aims to fully address compliance requirements with regard to relevant laws and regulations. Concurrently, the company is proposing to change its name from RYB Education to Gravitas Education, subject to approval at the next extraordinary general meeting. The divested kindergartens will continue to be operated by the current management team, ensuring consistency and continued delivery of high quality education to students. This divesture includes the termination of agreements by and among Beijing RYB Technology, Beijing RYB Children Education and its shareholders. As compensation for the termination of VIE agreements, an aggregate amount of RMB 158.5M will be paid in installments to its WFOE. Its WFOE has entered into service agreements at arm's length terms, following market prices and conditions, with its VIE. The audit committee of the board of the directors of the company, with the assistance of a third-party financial advisor, has independently reviewed and approved the divesture as a related party transaction at arm's length terms. The divesture proposal was submitted to the board of directors of the company, and was officially approved.